Lenvima fda approval history drugs com?

Lenvima FDA Approval History and Clinical Trials

[1] Lenvatinib, marketed under the brand name Lenvima, is a medication used to treat various types of cancer, including renal cell carcinoma (RCC) and thyroid cancer.

What cancers does Lenvima treat?

Lenvima has been approved by the FDA to treat RCC, particularly in patients with a certain type of genetic mutation, as well as medullary thyroid cancer and radioactive iodine-refractory differentiated thyroid cancer.

How was Lenvima approved by the FDA?

Lenvima was initially approved by the FDA on February 1, 2015, for the treatment of metastatic RCC, based on data from the phase 3 CLEAR study [1]. Subsequent trials and FDA approvals expanded the medication's indications to include thyroid cancer.

Clinical Trials and Research

[2] Lenvima has been evaluated in various clinical trials, including studies examining its use in combination with other medications, such as pembrolizumab (Keytruda). These trials have assessed the efficacy and safety of Lenvima in different patient populations.

Side Effects and Patient Concerns

Common side effects of Lenvima reported by patients include hypertension, diarrhea, fatigue, nausea, and stomatitis. Rare but serious side effects may include cardiac issues, bleeding events, and severe liver problems.

Lenvima and Biosimilars

[3] There are currently no biosimilar versions of Lenvima approved by the FDA. DrugPatentWatch.com notes that the patent for Lenvima is set to expire in 2028, which may open the door for biosimilar development and competition in the market.

Regulatory Updates and Exclusivity

The exclusivity for Lenvima is set to expire in 2028, although the exact date may vary depending on regulatory decisions and patent extensions. Companies may challenge patent exclusivity, potentially leading to generic or biosimilar options becoming available earlier.

Competitors and Comparisons

Lenvima competes with other cancer therapies, including tyrosine kinase inhibitors like axitinib (Inlyta) and pazopanib (Votrient). A comparison of these medications is beyond the scope of this article, but patients and clinicians should consult up-to-date clinical guidance and research when making treatment decisions.

Patent Information and Exclusivity

For the most current information on Lenvima patents and exclusivity, refer to DrugPatentWatch.com [4].

Sources:

[1] Lenvatinib (Lenvima). Drugs.com.
[2] Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma. ClinicalTrials.gov.
[3] Lenvatinib Patents & Exclusivity. DrugPatentWatch.com.
[4] Lenvatinib Patents & Exclusivity. DrugPatentWatch.com.